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Nitric oxide (NO) is a known anti-adhesive molecule that prevents platelet aggregation
and leukocyte adhesion to endothelial cells (ECs). The mechanism has been attributed to
its role in the regulation of adhesion molecules on leukocytes and the adhesive properties
of platelets. Our previous study conducted in rat venules found that reduction of EC
basal NO synthesis caused EC ICAM-1-mediated firm adhesion of leukocytes within
10–30 min. This quick response occurred in the absence of alterations of adhesion
molecules on leukocytes and also opposes the classical pattern of ICAM-1-mediated
leukocyte adhesion that requires protein synthesis and occurs hours after stimulation.
The objective of this study is to investigate the underlying mechanisms of reduced basal
NO-induced EC-mediated rapid leukocyte adhesion observed in intact microvessels.
The relative levels of ICAM-1 at different cell regions and their activation status
were determined with cellular fractionation and western blot using cultured human
umbilical vein ECs. ICAM-1 adhesiveness was determined by immunoprecipitation in
non-denatured proteins to assess the changes in ICAM-1 binding to its inhibitory
antibody, mAb1A29, and antibody against total ICAM-1 with and without NO reduction.
The adhesion strength of EC ICAM-1 was assessed by atomic force microscopy
(AFM) on live cells. Results showed that reduction of EC basal NO caused by the
application of caveolin-1 scaffolding domain (AP-CAV) or NOS inhibitor, L-NMMA, for
30 min significantly increased phosphorylated ICAM-1 and its binding to mAb1A29 in
the absence of altered ICAM-1 expression and its distribution at subcellular regions. The
Src inhibitor, PP1, inhibited NO reduction-induced increases in ICAM-1 phosphorylation
and adhesive binding. AFM detected significant increases in the binding force between
AP-CAV-treated ECs and mAb1A29-coated probes. These results demonstrated that
reduced EC basal NO lead to a rapid increase in ICAM-1 adhesive binding via
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Src-mediated phosphorylation without de novo protein synthesis and translocation.
This study suggests that a NO-dependent conformational change of constitutive EC
membrane ICAM-1 might be the mechanism of rapid ICAM-1 dependent leukocyte
adhesion observed in vivo. This new mechanistic insight provides a better understanding
of EC/leukocyte interaction-mediated vascular inflammation under many disease
conditions that encounter reduced basal NO in the circulation system.
Keywords: constitutive ICAM-1, ICAM-1-mediated leukocyte adhesion, basal nitric oxide, conformational change
of ICAM-1, atomic force microscopy

INTRODUCTION

ICAM-1 (Xu et al., 2013). The key observations derived in
intact microvessel studies (Xu et al., 2013) are presented
in Figure 1. However, the intact microvessel studies could
not provide mechanistic evidence addressing how reduced
basal NO increases ICAM-1-mediated early phase leukocyte
adhesion and whether the increased leukocyte adhesion is
caused by increased quantity of membrane expression of ICAM1 through translocation or purely due to the quality change
of constitutively expressed ICAM-1, namely by increasing its
adhesion capacity. This study conducted in cultured human
umbilical vein endothelial cells (HUVECs) is the extension
of our intact microvessel studies and aims to provide the
mechanistic insight for this important in vivo observation at
cellular and protein levels. We quantitatively measured realtime endothelial NO production in the absence and presence
of AP-CAV, an endogenous eNOS inhibitor, and L-NMMA,
and assessed the concomitant changes in sub-cellular quantity
of ICAM-1, adhesive binding avidity of ICAM-1, as well
as the signaling pathways involved in the activation status
of ICAM-1.

Nitric oxide (NO), in addition to being a potent vasodilator,
has been recognized to play dual roles in inflammation.
Excessive (pathogenic) NO production induced by inflammatory
conditions/mediators contributes to an increase in microvascular
permeability and plays a pro-inflammatory role (Moncada and
Higgs, 1993; Yuan et al., 1993; Mayhan, 1994; Wu et al., 1996; He
et al., 1997; Zhu and He, 2005; Hatakeyama et al., 2006; Sánchez
et al., 2008; Zhou and He, 2011b). In contrast, physiologic
(basal/constitutive) production of NO has anti-adhesive and
anti-inflammatory properties (Furchgott and Vanhoutte, 1989;
Ignarro, 1989; Moncada, 1992; Moncada and Higgs, 1993)
and plays a critical role in preventing leukocyte adhesion
(Kubes et al., 1991; Tsao et al., 1994) and the adhesion and
aggregation of platelets (Azuma et al., 1986; Radomski et al.,
1987a,c, 1990). Studies have shown that inhibition of basal NO
increased leukocyte and platelet adhesion to cultured endothelial
monolayers or vascular walls (Radomski et al., 1987b; Kubes et al.,
1991, 1993; Ma et al., 1993; Tsao et al., 1994). The mechanisms
were basically attributed to the direct or indirect roles of
NO/cGMP in the regulation of adhesion molecules on leukocytes
and the adhesive properties of platelets (Kubes et al., 1991,
1993; Ma et al., 1993; Tsao et al., 1994). A few studies indicated
that the reduction of NO by pharmacological approach, genetic
deletion of eNOS, or the over expression of caveolin-1 increased
the adhesiveness of endothelial cells (ECs) and EC-leukocyte
interaction (Radomski et al., 1987b; Ma et al., 1993; Tsao et al.,
1994; Fernández-Hernando et al., 2009, 2010; Atochin and
Huang, 2010; Ponnuswamy et al., 2012), but the mechanisms are
still unknown. Reduced basal NO synthesis or NO bioavailability
occurred in various disease conditions including hypertension,
diabetes, hypercholesterolemia, and reperfusion injury, and
was directly linked to endothelial dysfunction and vascular
inflammation (Dinerman et al., 1993; Moncada and Higgs,
1993, 2006; Potenza et al., 2009). A better understanding
of the underlying mechanisms of the anti-adhesive roles of
NO will further benefit the knowledge translation to clinical
applications.
Our previous study conducted in intact rat venules showed
that reduced endothelial basal NO synthesis caused by the
application of caveolin-1 scaffolding domain (AP-CAV) or
NOS inhibitor, L-NMMA, induces a large number of firmly
adhered leukocytes in about 10-30 min, which was blocked by
ICAM-1 blocking antibody, mAb1A29, and abolished by a NO
donor, indicating a NO-dependent regulation of endothelial
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MATERIALS AND METHODS
Endothelial Cell Culture and Treatments
Primary human umbilical endothelial cells (HUVECs),
endothelial growth media (EGM), and supplements were
purchased from Lonza (CC-3122 and CC-4133, Walkersville,
MD). HUVECs were seeded at a density of 2.5 x 103 cells per
cm2 and cultured in EGM with supplements containing bovine
brain extract, human epidermal growth factor, fetal bovine
serum, hydrocortisone, ascorbic Acid, GA-1000 (Gentamicin,
Amphotericin B), and heparin. The cell culture was performed
in a humidified atmosphere of 5% CO2 at 37◦ C. HUVECs
were split routinely when they reached 90% confluence and
used for experiments within 5 passages after purchasing.
Cells were treated with AP-CAV, the fusion peptide of CAV
scaffolding domain with AP, the Antennapedia internalization
sequence from Drosophila Antennapedia homeodomain
(synthesized by Tufts University), PP1, [(4-Amino-5(methylphenyl)-7-(t-butyl)pyrazolo-(3,4-d)pyrimidine, Sigma],
and/or N(Ω)-monomethyl-L-arginine acetate salt (L-NMMA,
Sigma) for 30 min or 6 h at a concentration of 10 µM. In some
experiments, PP1 was added 30 min prior to AP-CAV peptide
treatment. ECs cultured in petri dish were used for western blot,
and microfluidic devices were used for NO measurements. The
stock solutions of AP-CAV peptide, PP1, and L-NMMA were
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NO Measurements and Fluorescence
Imaging in HUVECs Cultured in
Microfluidic Channels
We recently demonstrated that ECs develop well-formed
junctions when grown with continuous flow in the
microchannels, and their intracellular calcium and nitric
oxide responses to ATP were similar to those observed in intact
microvessels (Li et al., 2015). In this study, cultured EC-formed
microvessel networks were used to measure changes in EC basal
NO production rate before and after AP-CAV or L-NMMA was
applied to the vessel lumen. The methods have been described
in detail (Zhou and He, 2011a; Li et al., 2015; Xu et al., 2016). In
brief, HUVECs were seeded into polydimethylsiloxane (PDMS)
microfluidic microchannel network device and cultured under
continuous perfusion with wall shear stress at 1.0∼2.0 dyne/cm2
within the network. Experiments were conducted after ECs
reached confluency (4∼5 days of perfusion). DAF-2 DA, a
membrane-permeable fluorescent indicator for NO (Sigma),
was used to measure EC NO. Since the chemical conversion of
DAF-2 in reaction of NO is irreversible, the changes of DAF-2
fluorescence (FIDAF ) represents the cumulative NO production.
The magnitude change of FI is time and rate dependent. So the
rate change of FIDAF , df/dt, or NO production rate, is the most
appropriate way to report the DAF-2 results. In this study, NO
production rate was reported, which was derived from FIDAF
profile in microvessel networks. Leica TCS SP8 confocal system
and Leica ×25 objective (NA: 0.95) were used for fluorescence
imaging. An optically pumped solid-state laser at 488 nm with
0.08% power was used for excitation, and a HyD detector was
used for the collection of the 510–545 nm emission. In each
experiment, the microvessel network was continuously perfused
with albumin-Ringer solution containing DAF-2 DA (5 µM).
After the DAF-2 loading reached steady state (about 40 min
perfusion), image stacks (xyz) were collected at 1 min interval
using 1,024 × 1,024 scan format and 0.5 µm z-step. In each
experiment, the images of FIDAF were collected under control
conditions first for calculation of basal NO production rate and
followed by the addition of 10 µM of AP-CAV or L-NMMA.
Sodium nitroprusside (SNP, 50 mM, Sigma), a NO donor, was
perfused at the end of the experiment to verify the sufficiency of
DAF-2 within ECs and the specificity of DAF-2 response to NO.
Image analysis and NO production rate calculations have been
described in detail (Zhou and He, 2011a).

FIGURE 1 | Perfusion of rat mesenteric venules with AP-CAV induced basal
NO-dependent ICAM-1 mediated leukocyte adhesion. Intact venules were
perfused by AP-CAV for 30 min followed by resuming blood flow in the same
vessel for 10 min. Leukocyte adhesion was quantified when each vessel was
recannulated with BSA-Ringer solution (Xu et al., 2013). (A) Video images of a
perfused venule under control conditions and after AP-CAV (10 µM)-induced
leukocyte adhesion, and the administration of a NO donor, sodium
nitroprusside (SNP), in both perfusate (10 µM) and superfusate (20 µM)
abolished AP-CAV-induced leukocyte adhesion. (B) AP-CAV induced
dose-dependent increases in EC ICAM-1 binding to its blocking antibody
mAb1A29. Confocal images of mAb1A29 (green) and vascular cell nuclei (red)
immunofluorescence co-staining under control conditions, after AP-CAV
perfusion, and after adding SNP to AP-CAV perfused vessels. (C) Perfusion of
vessels with ICAM-1 inhibitory antibody, mAb1A29, significantly attenuated
AP-CAV induced leukocyte adhesion (n = 5 per group). * and † indicate a
significant increase and decrease from the control, respectively (modified from
Xu et al., 2013 and used by original authors).

Subcellular Fractionation and Western Blot
Analysis
To investigate ICAM-1 expression at different subcellular
compartments, control and treated HUVECs were lysed as
whole cell, or into cytosolic and membrane fractions using a
standard Cell Fractionation Kit (ab109719, Abcam) for ICAM1 expression studies. All collected proteins were centrifuged at
12,000 × g for 15 min at 4◦ C, and the protein concentration was
measured by a BCA assay (Pierce). For each set of experiments,
equal amounts of protein (20∼25 µg/well) were loaded to 10%
SDS-PAGE gels (Bio-Rad Laboratories) for electrophoresis in
a Bio-Rad mini blot system (Life Technologies) at constant

prepared in 100% DMSO, and the final solution of each agent
was prepared by >1:1,000 dilution of the stock with EC culture
medium.

Frontiers in Physiology | www.frontiersin.org
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voltage of 90V, and transferred to nitrocellulose membranes (Life
Technologies) at constant current of 100 mA for 2 h at 4◦ C.
The membranes were then incubated at room temperature in
Odyssey blocking buffer (LiCor BioSciences) for 1 h, followed
by incubations with primary antibodies [1:1,000 for anti-VECadherin (Cat # 2500, Cell Signaling), anti ICAM-1 (1:1,000,
Cat # 4915S, Cell Signaling or Cat # 554966, BD Pharmingen),
and anti-β-actin (Cat # 8457, Cell Signaling), 1:500 for anti-pICAM-1 (phospho Y512, ab51033, Abcam)] at 4◦ C overnight,
and secondary antibodies [1:10,000 for IRDye800-conjugated
anti-mouse and anti-rabbit antibodies (Cat # 925-68071 and 92532211, LiCor BioSciences)] at room temperature for 1 h. Images
were visualized using a LiCor Odyssey Scanner and the bands
were quantified using Image Studio software (LiCor BioSciences).
All of the values were presented as ratio to the reference protein
in the same lane.

glass coverslips. Upon 80% confluence, the cells were treated
accordingly to the experimental protocol, and the coverslips
were then attached on a metal disc platform where the cells
were maintained with serum free EC culture medium. The
force measurement was carried out in aqueous solution with a
fluid cell containing HUVEC medium on a multimode AFM
with a Nanoscope IIIa control system (version 5.31r1, Veeco
Instruments, Santa Barbara, CA). ECs, AFM force curves (over
60 measurements in each group) were randomly acquired from
cultured EC surface (three separated areas at size of 60 µm
× 60 µm each) in the force mode at a vertical scan rate
of 1 Hz and ramp size of 25,00 nm. The trigger mode was
set with a deflection threshold of 50 nm. The retraction force
curves were extracted for the calculation of binding force, which
was defined as the product of spring constant and maximum
deflection of cantilever during the probe separation from sample
surface.

Immunoprecipitation Analysis
To investigate the mechanisms involved in increased
adhesiveness of ECs in response to reduced NO,
immunoprecipitation analysis was conducted in non-denatured
proteins. HUVECs under control conditions or after treatments
were collected with non-denaturing lysis buffer (20 mM
Tris HCl pH 8, 137 mM NaCl, 1% Triton X-100, 2 mM
EDTA, and protease inhibitors) for immunoprecipitation
analysis. All of the subsequent procedures were performed
according to manufacturer’s protocol. Briefly, protein G
Dynabeads IP kit was used (10007D, Life Technologies) for
binding of ICAM-1 blocking antibody (mAb1A29, 1:1,000,
Cat # 554966, BD Pharmingen) and antibody against total
ICAM-1 (1:1,000, Cat # 4915S, Cell Signaling) to magnetic
beads, immunoprecipitation of antigen, and elution of Ab/Ag
complex. Supernatants collected after elution were transferred
to clean tubes, and the immunoprecipitation samples were
then prepared for gel loading, electrophoresis, membrane
transfer, blocking, and incubations with ICAM-1 blocking
antibody, total ICAM-1 antibody, and anti-GAPDH antibody
(1:3,000, ab9485, Abcam), as described above for the western
blot.

Statistical Analysis
All numerical data were presented as mean ± SE for each group,
except where noted otherwise. Paired t-test was used for paired
data analysis. Unpaired t-test was used between two groups. OneWay ANOVA with post-hoc Tukey test was used to compare
the differences between groups of three or more. KolmogorovSmirnov test was performed to compare the distribution of
atomic force between control and AP-CAV-1 treated groups
and presented as median with 95% confidence interval. A
probability value of P < 0.05 was considered statistically
significant.

RESULTS
AP-CAV Inhibits Basal NO Production in
HUVECs Cultured in Microfluidic Channels
The effect of AP-CAV on basal endothelial NO production was
evaluated in four microfluidic devices with confluent HUVECs
in the microchannel network. The representative profile of
DAF-2 fluorescent intensity (FIDAF ) from ECs of microfluidic
channels was presented in Figure 2A. With albumin-Ringer
perfusion, FIDAF showed a slow increase at a constant rate of
0.14 ± 0.020 AU/min, which represents the rate of EC basal
NO production. When AP-CAV (10 µM) was added to the
perfusion of microfluidic channels, the rate of the FIDAF increase
significantly reduced from the basal level to a mean value of
0.04 ± 0.017 AU/min. We also compared the inhibitory effect of
AP-CAV on basal NO with that of a NOS inhibitor, L-NMMA.
In another set of four HUVEC microfluidic channels, the mean
rate of FIDAF increase in the presence of L-NMMA (10 µM)
was significantly reduced from the basal level of 0.15 ± 0.012
AU/min to 0.02 ± 0.005 AU/min. Results are summarized in
Figure 2B. Both the basal NO production rate and the magnitude
of basal NO reduction by AP-CAV or L-NMMA measured in
cultured HUVEC microchannels were similar to those measured
in individually perfused intact rat microvessels (Zhou and He,
2011a; Xu et al., 2013).

AFM Measurements of Cell Membrane
ICAM-1 Binding Force
The adhesive binding of cell membrane ICAM-1 to the blocking
antibody mAb1A29 was measured by AFM in ECs cultured
in petri dish with slight modifications of previously described
procedures (Xu and Siedlecki, 2010; Ozdemir et al., 2013).
Briefly, silicon nitride AFM probes (DNP, Bruker, spring constant
0.06 N/m) were first cleaned with acetone for 15 min, followed
by a 30 min of air plasma treatment, and then incubation
with 1% aminopropyltriethoxysilane solution in ethanol for
1 h. After three times of rinse with deionized (DI) water,
the probes were incubated with 10% glutaraldehyde solution
for 1 h to provide a cross linking site. After three times of
additional washing with DI water, probes were then incubated
with ICAM-1 blocking antibody (25 µg/ml, mAb1A29) for 1 h
and stored in phosphate-buffered saline (PBS) until use within
2 days. HUVECs were seeded on collagen-coated (0.5 mg/ml)

Frontiers in Physiology | www.frontiersin.org
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6 h treatments with AP-CAV peptide. Under control conditions,
the mean ICAM-1 expression in the cell membrane is higher
than that in the cytosol, but not statistically different. After APCAV (10 µM) treatments, we observed no significant changes in
ICAM-1 expression from that of the control in both whole cell
and subcellular fractions (Figure 3, P > 0.05, n = 3 per group),
indicating that AP-CAV has no effect on either de novo synthesis
or translocation of EC ICAM-1. The cellular fractionation
process was validated by the differentiated distributions of
EC membrane protein VE-cadherin that showed dominated
expressions in the membrane fraction and minimum in cytosol
(Figure 3A).

AP-CAV Increases ICAM-1 Binding
Strength to Its Blocking Antibody: Binding
Force Measurements
The western blot analysis with no AP-CAV-induced changes in
ICAM-1 expression in all subcellular compartments suggested
that reduced basal NO by AP-CAV might increase the
adhesiveness of constitutive ICAM-1 in EC (Xu et al., 2013).
To test this possibility, AFM was used to measure the binding
strength of EC ICAM-1 to its blocking antibody mAb1A29.
The representative retraction force curves on various surfaces
are illustrated in Figure 4A. When ICAM-1 antibody coated
AFM probes compressed and then retracted from the EC
membrane (Figure 4A, control), the force curves showed a
gradually decreased value compared to the steeper curve slope
on the glass surface (Figure 4A, glass). The steepness of force
curve was used to determine whether the probe landed on
the cell membrane surface or not. When a probe without
antibody coating was used for detection, there was no abrupt
shift as the probe separated from the cell surface, indicating no
binding event occurred between probe and cell membrane. In
contrast, ICAM-1 antibody coated probe displayed the saw-like
force curve, indicating multiple debonding events simultaneously
occurred in the separation region when the probe retracted from
cell membranes. Results showed that AP-CAV (10 µM)-treated
ECs markedly increased the debonding force compared to that
measured on control cells. The median binding strengths in
control and AP-CAV treated cells were 0.14 nN and 0.34 nN,
respectively (Figure 4B, P < 0.05, n > 60). Figure 4C shows
significantly different distributions of binding strength measured
in control and AP-CAV treated cells (P < 0.0005), indicating an
increased binding strength between EC ICAM-1 and its blocking
antibody in AP-CAV-treated cells.

FIGURE 2 | AP-CAV or NOS inhibitor reduced basal NO production in
HUVECs cultured in microchannels of microfluidic devices. (A) A representative
experiment showing the time-dependent changes of DAF-2 fluorescence
(FIDAF ) before and after AP-CAV (10 µM) application. Arrow indicates the time
point when AP-CAV was perfused into the microfluidic device. (B) Summary of
NO production rate derived from FIDAF profiles (n = 4 per group). **P < 0.005,
***P < 0.0005. NS indicates no significant differences.

AP-CAV-Induced Basal NO Reduction
Does Not Alter ICAM-1 Expression and
Constitutive ICAM-1 Subcellular
Distribution
Our previous study observed significant increases in firmly
adhered leukocytes to rat venules after perfusion of vessels
with AP-CAV for about 30 min, and pre-perfusing vessels with
ICAM-1 blocking antibody, mAb1A29, prevented such adhesion,
indicating that the adhesion process was mediated by AP-CAVinduced changes in endothelial ICAM-1 (Xu et al., 2013). The
short timing of AP-CAV-induced leukocyte adhesion basically
ruled out the possibility of de novo ICAM-1 synthesis, but
the intact microvessel study could not distinguish if AP-CAVinduced ICAM-1-mediated leukocyte adhesion was the result
of increased membrane ICAM-1 through its translocation from
cytosol or purely an increase in the binding capacity and/or
binding affinity of constitutive membrane ICAM-1 to leukocytes.
In this study, we first evaluated ICAM-1 expressions at different
fractions of ECs by western blot analysis following 30 min and

Frontiers in Physiology | www.frontiersin.org

Reduction of Basal NO Caused a Quick
Increase in EC ICAM-1 Adhesive Binding
Avidity without Altering ICAM-1
Expression: Immunoprecipitation Assay in
Non-denatured Proteins
To investigate if the AP-CAV-mediated increases in EC
adhesiveness is directly related to increased ICAM-1 binding to
its counter ligand, immuno-precipitation assays were performed
in non-denatured cell lysate to assess the changes in ICAM-1
binding to its blocking antibody, mAb1A29, and compared with
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FIGURE 3 | AP-CAV application shows no effect on ICAM-1 expression at whole cell and subcellular fractions of HUVECs. (A) Western blot showed no significant
changes in ICAM-1 expression in whole cell (W), membrane (M), and cytosol (C) of HUVECs after AP-CAV (10 µM) treatment for 30 min or 6 h, respectively.
VE-Cadherin, a membrane bound protein, that was only evident in the membrane and whole cell validated the cell fractionation procedure. (B) Summary of ICAM-1
expression in whole cell and subcellular fractions of HUVECs under control conditions. (C–E) Result summary showing no significant changes of ICAM-1 expression
after AP-CAV (10 µM) treatment for 30 min or 6 h in whole cell and subcellular locations. n = 3 per group. **P < 0.005; NS indicates no significant differences.

its binding to antibody against total ICAM-1 under identical
experimental conditions. Data shown in Figure 5 demonstrated
that both 30 min and 6 h of AP-CAV (10 µM) treatment
increased bound mAb1A29-ICAM-1 compared to the untreated
control group (n = 3 per group). To further confirm reduced
basal NO to be the cause of AP-CAV-mediated increase in ICAM1-mAb1A29 complex, NOS inhibitor, L-NMMA (100 µM), was
applied to cells for 30 min and 6 h, respectively. The results
were comparable to that of AP-CAV (n = 3 per group). We
also examined the involvement of Src signaling in such effects.
A Src kinase inhibitor, PP1 (10 µM), was applied to cells
before AP-CAV treatment. As shown in Figures 5A3,A4, pretreatment of cells with PP1 significantly attenuated AP-CAVinduced increases in ICAM-1-mAb1A29 complex (n = 3 per
group). The ICAM-1 binding to antibody against total ICAM1 was also assessed under identical experimental conditions to
those using mAb1A29. In contrast to the results of mAb1A29,
both AP-CAV and L-NMMA treatments showed no effect on
ICAM-1-antibody for total ICAM-1 binding compared to the

Frontiers in Physiology | www.frontiersin.org

control (Figure 5B). These results indicate that reduction of
basal NO increased its binding to its counter ligand without
changing its protein expression, and this action is mediated by
Src signaling.

AP-CAV-Mediated Basal NO Reduction
Increases the Adhesiveness of ICAM-1 via
Src-Mediated ICAM-1 Phosphorylation
The findings that Src kinase inhibitor significantly attenuated
AP-CAV-induced increase in ICAM-1/mAb1A29 binding
(Figure 5A) lead us to examine whether Src-mediated
phosphorylation of ICAM-1 is involved. We determined
the expression levels of phosphorylated ICAM-1 (p-ICAM-1)
relative to the total ICAM-1 in the absence and presence of
AP-CAV (10 µM). Figure 6A shows the representative results
of western blot. The summary results shown in Figures 6B,C
demonstrated that the application of AP-CAV (10 µM)
significantly increased p-ICAM-1 in HUVECs compared
to untreated control group (n = 3 per group). The similar
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results observed with LNMMA application further support
the reduced basal NO by AP-CAV to be the mechanism of
ICAM-1 activation. Figures 6D,E show that pre-treatment of the
cells with PP1 (10 µM, 30 min) significantly reduced AP-CAVinduced increases in p-ICAM-1 (n = 3 per group). The role of
Src signaling in ICAM-1 activation was further evaluated with
Src kinase inhibitor at different dosages. Figure 7 shows that Src
kinase inhibitor, PP1, at concentrations between 5 and 20 µM
showed graded inhibition of AP-CAV- and L-NMMA-induced
increases in p-ICAM-1 (n = 3 per group). The p-ICAM-1 levels
with 20 µM of PP1 treatment were not significantly different
from that of the control, indicating a complete inhibition. These
results indicate that reduced basal NO activates constitutive
ICAM-1 via Src-mediated phosphorylation.

DISCUSSION
This study revealed a novel mechanism of NO-dependent
changes in EC adhesiveness that had been observed in intact
microvessels (Xu et al., 2013). The major new findings are
that reduction of endothelial basal NO by direct inhibition of
endothelial eNOS with AP-CAV or L-NMMA induced a rapid
activation of constitutively expressed endothelial ICAM-1 via
Src-mediated phosphorylation, resulting in increases in adhesive
binding of ICAM-1. The identified mechanism explained our
previous observation that reduced endothelial basal NO quickly
induces ICAM-1-mediated firm adhesion of leukocytes to rat
venules (Xu et al., 2013). Most importantly, the reduction of
basal NO-induced increases in ICAM-1 adhesiveness occurred
in the absence of de novo protein synthesis and translocation,
suggesting a NO-dependent regulation of the adhesive binding
avidity of constitutively expressed endothelial ICAM-1. These
findings provide new insights into the mechanisms whereby
reduced basal NO increases the adhesiveness of endothelial
cells and contributes to early phase leukocyte adhesion to
microvessels.

Inhibition of Basal NO Synthesis in
Cultured HUVECs
In this study the inhibition of endothelial basal NO was achieved
by the application of an eNOS endogenous inhibitor, APCAV, and confirmed by a NOS inhibitor, L-NMMA. eNOS is
constitutively expressed in the caveolae and colocalizes with
CAV-1 (Feron et al., 1996; García-Cardeña et al., 1997). Under
basal conditions most of the eNOS is associated with scaffolding
domain of CAV-1, which tonically inhibits eNOS activation and
function (Bucci et al., 2000; Fleming, 2010). In the CAV-1-null
mice, eNOS activity is upregulated because of the loss of CAV1 (Drab et al., 2001; Razani et al., 2001), and functional studies
showed that CAV scaffolding domain peptide can selectively
regulate signal transduction to endothelial eNOS both in intact
blood vessels and cultured aortic endothelial cells (Bucci et al.,
2000; Bernatchez et al., 2005). Those studies thus indicated
CAV-1 as an endogenous inhibitor of eNOS. We have also
demonstrated that application of AP-CAV in intact microvessels
inhibits platelet activating factor (PAF)-induced NO production

FIGURE 4 | Reduced endothelial basal NO by AP-CAV increases the binding
strength of live cell membrane ICAM-1 to its blocking antibody. (A) Force
curves differ between groups (contacting surfaces with and without cultured
ECs, probes with and without coated ICAM-1 blocking antibody, and cultured
ECs with and without exposure to AP-CAV). The curve with a gradual
decrease indicates the adhesive interaction between ICAM-1 blocking
antibody (on probe) and ICAM-1 on EC membrane. (B) Result summary
showing that 30 min application of AP-CAV (10 µM) significantly increased EC
ICAM-1 adhesive strength. Values shown are median with 95% confidence
interval. C) The distribution of each measured force value in control and
AP-CAV treated cells. More than 60 measurements were acquired in three
separate cell surface areas (60 µm × 60 µm each) in each cell group.
Kolmogorov-Smirnov test was performed to compare the distribution
differences between two groups. *P < 0.05, ***P < 0.0005.
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FIGURE 5 | Immuno-precipitation assay conducted in non-denatured proteins showing that reduction of basal NO increases the adhesiveness of EC constitutive
ICAM-1 via Src-dependent pathway. (A) Reduced basal NO increased EC ICAM-1 binding to its inhibitory antibody. mAb1A29. The application of AP-CAV (10 µM) or
L-NMMA (100 µM) for 30 min (A1) or 6 h (A2) significantly increased ICAM-1 binding to its blocking antibody. Pre-treatment of ECs with Src kinase inhibitor, PP1
(10 µM), significantly attenuated the effect of AP-CAV, indicating the involvement of Src signaling (A3,A4). (B) In contrast to the results shown in A, reduction of basal
NO did not change ICAM-1 binding to antibody against total ICAM-1, indicating no changes in ICAM-1 expression. AP-CAV (B1) or L-NMMA (B2) treatment for
30 min with or without PP1 did not alter ICAM-1 binding to antibody against total ICAM-1. n = 3 for all IP and western blot assays. *P < 0.05, **P < 0.005,
***P < 0.0005, NS indicates no significant differences.

Frontiers in Physiology | www.frontiersin.org

8

January 2018 | Volume 8 | Article 1124

Gao et al.

Reduced NO Increases ICAM-1 Adhesiveness

FIGURE 6 | The increased adhesiveness of EC ICAM-1 induced by basal NO reduction is associated with Src signaling-mediated phosphorylation of constitutive
ICAM-1. (A) Western blot showing phosphorylated ICAM-1 (p-ICAM-1) relative to total ICAM-1 significantly increased after HUVECs were exposed to AP-CAV (10 µM)
or L-NMMA (100 µM) for 30 min (B), or 6 h (C). Pre-exposure cells to 10 µM PP1 significantly attenuated the effect (D,E). n = 3 for western blot. *P < 0.05,
**P < 0.005, ***P < 0.0005, NS indicates no significant differences.

and NO-mediated increases in microvessel permeability (Zhu
et al., 2004; Xu et al., 2013). Using a newly developed method
to measure basal NO with continuous perfusion of NO indicator
DAF-2 DA (Zhou and He, 2011b), we were the first to show
that AP-CAV reduces endothelial basal NO production without
affecting basal microvessel permeability, but promotes ICAM1-mediated firm leukocyte adhesion in intact rat mesenteric
venules (Xu et al., 2013). Using this NO detection technique
along with an improved cell culture with microfluidic devices
(Li et al., 2015; Xu et al., 2016), this study provides direct
evidence that exogenously applied AP-CAV suppresses real-time
basal NO production in cultured HUVECs, and these findings
are consistent with our earlier study in intact microvessels (Xu
et al., 2013). With validated basal NO reduction by AP-CAV or

Frontiers in Physiology | www.frontiersin.org

L-NMMA, we further investigated the mechanisms of reduced
basal NO-induced leukocyte adhesion in intact microvessels.

The Role of Basal NO in the Regulation of
the Adhesiveness of Constitutively
Expressed Endothelial ICAM-1
The role of basal NO in preventing leukocyte-EC interaction,
platelet adherence and aggregation has been well documented
previously (Azuma et al., 1986; Radomski et al., 1987a,c,
1990; Kubes et al., 1991). During inflammatory process, NO
has been shown to modulate the expression of adhesion
molecules, leukocyte adhesion and migration, and the secretion
of inflammatory mediators (Kubes et al., 1991; Ma et al., 1993;
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FIGURE 7 | The role of Src signaling in NO-dependent phosphorylation of constitutive ICAM-1. (A) Western blot shows dose-dependent inhibition of phosphorylated
ICAM-1 (p-ICAM-1) relative to total ICAM-1 by Src kinase inhibitor, PP1, after ECs were exposed to AP-CAV or L-NMMA. (B) Application of AP-CAV (10 µM) for 30 min
significantly increased p-ICAM-1. PP1 at 5, 10, or 20 µM showed graded inhibition of increased p-ICAM-1. (C) L-NMMA (100 µM)-induced increases in p-ICAM-1
was inhibited by PP1 in a manner similar to that of AP-CAV. n = 3 for all experiments. *P < 0.05, **P < 0.005, ***P < 0.0005, NS indicates no significant differences.

Granger and Kubes, 1994; Tsao et al., 1994). The leukocyte-EC
adhesion in microcirculation has been characterized as a cascade
of coordinated interactions mediated by different adhesion
molecules (Carlos and Harlan, 1994; Granger and Kubes, 1994),
and the firm adhesion of leukocytes in the classical pattern of
leukocyte-EC interaction is mediated by increased expressions
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of ICAM-1 that requires transcription and translation of new
proteins and occurs several hours after cytokine-mediated
activation (Wertheimer et al., 1992; Carlos and Harlan, 1994;
Granger and Kubes, 1994). ICAM-1 is thus considered a critical
regulator of late phase leukocyte-EC interactions. In contrast
to classical pattern of leukocyte adhesion, we demonstrated
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that reduced basal NO, caused by AP-CAV or L-NMMA, not
only leads to rapid (within 10–20 min) but also firm adhesion
of leukocytes in intact rat venules (Figures 1A,C; Xu et al.,
2013). Immunofluorescence staining demonstrated increases in
endothelial ICAM-1 binding to its blocking antibody within
30-min of AP-CAV perfusion (Figure 1B; Xu et al., 2013).
Although the timing of increased ICAM-1 binding to its blocking
antibody was not in the time zone of new ICAM-1 synthesis, the
possibility of increased membrane ICAM-1 expression through
translocation could not be ruled out in our earlier study.
The regulation of endothelial adhesion molecules involves both
quantitative changes in the surface expression and qualitative
changes in the avidity (Carlos and Harlan, 1994; van de Stolpe
and van der Saag, 1996). In this study, cellular fractionation and
western blot analysis revealed that the majority of the ICAM-1
was localized in the cell membrane and there was no difference in
the subcellular expression levels of ICAM-1 between untreated
control and AP-CAV or L-NMMA treated cells. These findings
thus demonstrated that, in our experimental conditions, AP-CAV
treatment neither causes the membrane translocation nor the
protein synthesis of ICAM-1.
Since no quantity change and translocation of ICAM-1
were identified following the reduction of basal endothelial
NO, we then examined the role of NO in the regulation of
the adhesiveness of constitutively expressed ICAM-1 on ECs.
Monoclonal antibody, mAb1A29, is a specific functional
inhibitory antibody against ICAM-1 adhesion sites. Its
application inhibited ICAM-1-dependent leukocyte adhesion in
whole animal (Morisaki et al., 1997) and in individually perfused
intact microvessels (Xu et al., 2013). AFM measurements
showed a significant increase in debounding force between
the cell membrane ICAM-1 in AP-CAV-treated cells and
mAb1A29-coated probe. The detected higher magnitude of
debonding force supports that the increased adhesive binding of
constitutive ICAM-1 contributes to AP-CAV-induced leukocyte
adhesion observed in intact microvesels. This increased adhesive
binding force was further confirmed by immunoprecipitation
studies conducted in non-denatured proteins where we
showed increased binding between cell membrane ICAM-1
and mAb1A29 in AP-CAV treated cells. The similar effect
observed in NOS inhibitor, L-NMMA, treated cells further
supports that the AP-CAV effect was caused by reduced NO.
In contrast, no changes in binding complexes associated with
ICAM-1 were observed in immunoprecipitation studies using
antibody against total ICAM-1 under the identical experimental
conditions. These results suggest that the reduced basal NOinduced increases in adhesiveness of ECs could be the result of
increased adhesive binding of ICAM-1 to its counter ligands
without membrane ICAM-1 translocation or net increases in
protein expression. The increased adhesive binding avidity
could be the result of increased adhesion binding sites due
to structural conformational change or increased binding site
affinity of ICAM-1. Our current study at cellular and protein
levels demonstrates increases in adhesion binding avidity, but
is limited in further differentiating between binding capacity,
binding affinity, or a combination of both. We speculate that
the increased exposure of adhesive binding sites is likely to be
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involved, but direct supporting evidence has to rely on structural
analysis at single molecule level.

Src Signaling in Reduction of Basal
NO-Induced Activation of EC Constitutive
ICAM-1 with Increased Adhesive Binding
Avidity
Activation of cell adhesion molecules has been shown to
involve multiple signaling pathways, such as non-receptor
tyrosine kinases (Src), calcium, RhoA, phosphatidylinositol 3
kinase (PI3K), mitogen activated protein kinases, and NFκB
(Adamson et al., 1999; Etienne-Manneville et al., 2000; Wang
and Doerschuk, 2001; Lin et al., 2005; Allingham et al., 2007).
Src-dependent phosphorylation of EC ICAM-1, independent of
de novo protein synthesis, has been reported for TNFα-induced
increase in ICAM-1 binding avidity and early phase leukocyte
adhesion in both lung microvessels and cultured ECs (Liu et al.,
2011). Our recent study also showed that reduced NO-mediated
ICAM-1 phosphorylation and early leukocyte adhesion involves
Src signaling pathway in intact microvessels (Xu et al., 2013).
In this study, the Src kinase inhibitor showed inhibitory effect
on both inhibitory antibody binding to ICAM-1 and p-ICAM1 when basal NO was reduced, which strongly supports the
role of Src signaling in ICAM-1 activation. More importantly
the dose-dependent inhibition of ICAM-1 phosphorylation by
PP1 provided further supporting evidence, especially 20 µM
of PP1 basically reduced the p-ICAM-1 level insignificant to
that of the control, indicating a complete inhibition. These
findings are consistent to our earlier observations that reduced
basal NO promotes activation of ICAM-1 via Src-mediated
phosphorylation (Xu et al., 2013).

Comparison of This Study with Studies
Using eNOS Knock Out Animals
Genetic deletion of eNOS or over expression of caveolin-1 has
shown increased leukocyte EC interaction, aggravated infection
under disease conditions, and accelerated atherosclerosis in
apolipoprotein E (apoE) deficient mice (Sasaki et al., 2003;
Fernández-Hernando et al., 2009, 2010; Atochin and Huang,
2010; Fritzsche et al., 2010). Those studies indicated an important
role of NO in maintaining vascular function and preventing
vascular inflammation, but the mechanisms were not well
defined. ApoE/eNOS double knock out mice show significant
reduction of superoxide production, but increased leukocyte/EC
interaction, macrophage infiltration in carotid arteries, and
vascular cell adhesion molecular 1 (VCAM-1) expression in
both endothelial and smooth muscle cells compared to apoE−/−
alone, suggesting a NO-dependent and ROS-independent
mechanism to be involved in increased leukocyte/EC interaction
(Ponnuswamy et al., 2012). The eNOS knockout animals basically
represent a constantly reduced NO condition that may trigger
some adaptation and compensatory effects in the vascular system.
Therefore, the observed inflammatory manifestation is the results
of an integration of multiple factors and signaling pathways. Our
single vessel studies as that demonstrated in Figure 1 (Xu et al.,
2013) enabled us to define the mechanisms involved in ECs, but
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has to rely on cultured cells or extracted proteins to provide
further details. The main focus of our current study is to identify
the mechanisms involved in a rapid EC response to reduced basal
NO, which represents EC actions to acute or local NO production
changes under physiological or pathological conditions, which
could not be achieved using eNOS knockout animals. We are
also cautious about the potential phenotype differences between
cultured HUVECs and ECs in intact rat vessels. In this study,
the basic results derived from cell culture studies have been
consistent to our intact vessel findings. Importantly, the in vitro
study enabled us to reveal the mechanisms at cellular and protein
levels.
In Summary, ICAM-1 is constitutively expressed at low levels
on ECs and it is indispensable for the normal functioning
of the immune system (van de Stolpe and van der Saag,
1996), but its increased expression during inflammation or
after stimulation by pro-inflammatory cytokines contributes
to leukocyte/endothelial interaction and vascular inflammation
(Rothlein et al., 1986; Granger and Kubes, 1994; Hubbard and
Rothlein, 2000). On the other hand, constitutively expressed
eNOS continuously produces a low level of NO and this basal
NO acts as an endogenous inhibitor of leukocyte adhesion,
activation and chemotaxis (Furchgott and Vanhoutte, 1989;
Ignarro, 1989; Kubes et al., 1991; Moncada, 1992; Tsao et al.,
1994). Despite accumulating evidence that ICAM-1 mediates
adhesion and extravasation of leukocytes to and through
the endothelium (Carlos and Harlan, 1994) and endogenous
NO modulates leukocyte adherence through the expression of
adhesion molecules on leukocyte and ECs (Kubes et al., 1991;
Tsao et al., 1994), the underlying signaling mechanisms of
reduced NO-mediated increases in adhesiveness of microvessel
remained poorly understood. It has been proposed that eNOSderived NO does not directly modulate EC conversion to a proadhesive phenotype but rather interferes with the generation
of ROS by NADPH oxidase and prevents ROS-mediated
inflammatory response (Niu et al., 1994; Kvietys and Granger,
2012). In contrast to this proposal, the timing and pattern of

leukocyte adhesion in our previous study strongly supported a
direct association between basal NO and adhesive states of ECs
(Xu et al., 2013). Our present in vitro study on CAV-induced basal
NO reduction directly demonstrated that basal NO is essential
for maintaining the non-adhesive state of endothelium through
regulation of the adhesive binding of endothelial ICAM-1. The
reduced basal NO-induced increases in EC adhesive binding
were mediated by Src-dependent ICAM-1 activation through its
phosphorylated state. Although the potential structural changes
of ICAM-1 that resulted in increased adhesion avidity following
Src-mediated ICAM-1 activation remain to be elucidated, this
study provides new insights into the mechanisms how reduced
basal NO could mediate leukocyte adhesion to ECs. Importantly,
these findings could be of greater importance not only in
understanding the early pathologic stages of various clinical
conditions where reduced endothelial-derived NO plays a
central role in endothelial dysfunction, but also to the future
therapeutic approaches in inflammation-induced endothelial
dysfunction.
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